1. Levin L. Neurobiologic rationale for neuroprotection. In: Weinreb RN, ed. Glaucoma Neuroprotection. Philadelphia: Wolters Kluwer Health; 2006:1–7.
2. Takada M, Araie M, Suzuki Y, Koseki N, Yamagami J. The central visual field defects in low-tension glaucoma. A comparison of the central visual field defects in low-tension glaucoma with those in primary open angle glaucoma. Nippon Ganka Gakkai Zasshi. 1993;97(11):1320–1324.
3. Araie M, Yamagami J, Suziki Y. Visual field defects in normal-tension and high-tension glaucoma. Ophthalmology. 1993;100(12):1808–1814.
4. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38(1):83–91.
5. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99(10):1499–1504.